Press Releases

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
  • Record consumer revenue of $43 million increased 108% compared to Q2 2021
  • Ingredients sold out in first half with $15 million backlog to be supplied in H2
  • Cost actions and price increases to deliver $50 million of EBITDA improvements in H2
  • $700 million non-equity funding and earnout provides liquidity to sustained profitability

EMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022.

"Q2 2022 Core revenue of $65.2 million grew 54% versus Q2 2021 and was driven by record consumer revenue of $43.0 million, a 108% year-over-year increase for the quarter and 113% growth year-to-date, which compares to 16% for the U.S. prestige beauty sector," commented John Melo, President and Chief Executive Officer. "All of our distribution channels are performing well. Our omnichannel strategy is delivering strong growth with our retail channel representing 55% of Q2 consumer revenue as consumers increasingly resume in store experiences and purchasing, and 45% attributable to direct-to-consumer ecommerce. In the second quarter, our consumer products were on the shelves in 9,000 stores which compares to 1,500 in the year ago quarter. This number is rapidly expanding with thousands of Walmart stores being added."

"We are very pleased with the strong operational performance and execution across our business. We delivered the most rapid growth rate of any major consumer beauty company in the categories we compete in during the quarter. The start-up of our greenfield state-of-the-art bio-fermentation facility in Barra Bonita, Brazil was a major strategic milestone, and we completed two acquisitions, one of which was a new manufacturing facility for cosmetics and personal care products in Brazil. We are transitioning to lower cost fulfillment and away from China sourced packaging materials to mitigate supply chain issues, reduce freight expense and improve overall resiliency of our supply chain. We deepened our relationship with the world's leading retailers and sold all of the ingredients we produced in the quarter. We also made significant progress with the setup of infrastructure for our expansion into Europe."

"During the first half of this year, we have delivered on our plan to make significant investments in our infrastructure, along with increasing the scale of our consumer business. We are transitioning to harvesting these investments and expect to deliver $50 million in EBITDA improvements during the second half from a combination of price increases, SG&A reduction from leveraging marketing spends across the portfolio, reducing our manufacturing costs, and lower packaging and fulfillment costs across our consumer brands.

"We are moving beyond the period of significant investment and the constraints on our ingredients production capacity. We are entering the second half with a consumer business that we expect to deliver accelerated growth year-over-year, and a $15 million ingredient backlog for shipping in the second half. We have a robust outlook for the remainder of the year and our guidance remains intact. We have visibility to over $700 million of funding and cash inflow from earnouts with $200 million expected during the third quarter. We have built the leading clean beauty consumer brands, which are accelerating the reach of our Lab-to-Market technology. We are just getting started as the world's leading developer and producer of clean, sustainable chemistry."

Q2 and H1 2022 Sales Revenue

Core revenue comprises consumer and technology access revenue. Technology access includes ingredient product revenue, R&D collaboration, and technology licenses. Core revenue excludes strategic transactions and other one-off items.


Three Months,
 Ended June 30,


Six Months Ended
June 30,

 (In millions)

2022

2021

YoY%


2022

2021

YoY%

Consumer

$43.0

$20.7

108 %


77.5

36.3

113 %

Technology Access

22.2

21.6

3 %


45.4

39.0

16 %

Core 

65.2

42.3

54 %


122.9

75.4

63 %

Strategic Transactions/One-Off Items1

0.0

10.0

-100 %


0.0

153.8

-100 %

Reported Total

$65.2

$52.3

25 %


122.9

229.2

-46 %









 

1Strategic Transactions/One-Off Items includes $143.6m DSM F&F transaction (Q1 2021); $0.2m discontinued ingredients value share (Q1 2021); and $10.0m Ingredion RebM transaction (Q2 2021)

Q2 2022 Financial Highlights

  • Core revenue of $65.2 million increased 54% compared to Q2 2021 revenue of $42.3 million. Q2 2022 core revenue included record consumer revenue of $43.0 million, an increase of $22.3 million or 108% and technology access revenue of $22.2 million, an increase of 3% compared to the prior year quarter. Consumer and ingredients product revenue grew in each of our geographic markets.
  • Total reported revenue of $65.2 million increased 25% compared to the prior year quarter.
  • Consumer growth was driven by solid year-over-year growth of Biossance® and strong contributions from new brands, led by JVNTM, Rose Inc.TM and MenoLabsTM. Direct-to-consumer sales, which comprised 45% of total consumer sales, grew approximately 98% year over year. In-store and online retail sales, which comprised 55% of total consumer sales, grew approximately 111% year over year. Revenue from Sephora grew approximately 25% year-over-year. During the second quarter, Amyris brands were available at approximately 9,000 physical locations compared to approximately 1,500 during Q2 2021.
  • Technology access grew primarily due to increased technology license revenue, partially offset by the production campaign timing of an F&F ingredient. This is normal for Amyris' ingredients business, which is campaign driven and not seasonal. Sales of the highest demand ingredients, squalane and hemisqualane, encountered capacity constraints, but are well-positioned for strong growth in the second half of 2022. During the quarter, Amyris commenced production at its state-of-the-art large-scale precision fermentation plant in Barra Bonita, Brazil enabling the shipping of $15 million in ingredient backlog starting in the third quarter.
  • Non-GAAP core gross margin of $28.4 million, or 44% of revenue, increased from $16.5 million, or 39% of revenue in Q2 2021. Increased gross margin in Q2 2022 reflects a year-over-year increase in technology license revenue which was partially offset by lower average consumer gross margins due to brand portfolio and channel mix, higher ingredients input costs due to unfavorable contract manufacturing economics, and lower R&D collaboration revenue.
  • Gross profit of $11.7 million or 18% of revenue was on par with the prior year quarter, excluding the $10.0 million from the Q2 2021 strategic transaction, but down 10 percentage points due to a significant increase in freight and logistics expense related to higher rates and increased airfreight to support three new brands and the build of safety stock to address external supply chain challenges.
  • Cash operating expense of $136.7 million increased by $73.7 million compared to Q2 2021 due to an increase of $56.8 million in selling expense, $14.3 million in G&A expense, and $2.6 million in R&D expense. The increases were principally related to selling expense and driven by a combination of increased headcount (both organic and from acquisitions), significant investments in both existing and developing brands for paid media and advertising, expanded retail and ecommerce sales in the U.S. and internationally, growth-driven consumer order fulfillment and shipping expense and comparatively low prior year travel expense due to COVID-19.
  • Adjusted EBITDA of -$125.0 million decreased $73.9 million, excluding the $10.0 million from the Q2 2021 strategic transaction, primarily due to higher operating expense, and freight costs which include significantly higher levels of air shipping.
  • GAAP net income/loss was significantly influenced by non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives. GAAP net loss of $110.0 million, or a loss of $0.34 per share, compared to net income of $15.4 million, or $0.05 per share, in Q2 2021.
  • Cash at the end of Q2 2022 was $106.5 million, compared to $292.7 million at the end of Q1 2022.

H1 2022 Financial Highlights

  • Total revenue of $122.9 million decreased 46% compared to the prior year period which included $153.8 million of proceeds from strategic transactions.
  • For the first half of 2022, core revenue of $122.9 million increased 63% compared to H1 2021 revenue of $75.4 million. H1 2022 core revenue included record consumer revenue of $77.5 million, an increase of 113% compared to 2021, and technology access revenue of $45.4 million, an increase of 16% compared to 2021.
  • Non-GAAP core gross margin of $55.2 million, or 45% of revenue, increased from $33.5 million or 44% of revenue in H1 2021.
  • Gross profit of $21.3 million or 17% of revenue was below prior year due to a significant increase in freight and logistics expense
  • Cash operating expense of $253.8 million increased by $137.2 million, compared to H1 2021 primarily due to an increase of $102.9 million in selling expense, $28.2 million in G&A expense, and $6.1 million in R&D expense. The increases were primarily driven by a combination of increased headcount (both organic and from acquisitions), brand investments in paid media and advertising, growth-driven consumer order fulfillment and shipping expense, and comparatively low prior year travel expense due to COVID-19.
  • Adjusted EBITDA of -$232.5 million, decreased $140.1million, excluding the $153.8 million from the H1 2021 strategic transactions, primarily due to higher operating expense, and freight costs.
  • GAAP net loss was significantly influenced by non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives. GAAP net loss was $217.3 million, or a loss of $0.69 per share, compared to a loss of $274.8 million, or a loss of $0.98 per share, in H1 2021.

2022 Financial Outlook

Reiterating full year core revenue outlook: consumer revenue is expected to grow more than 150% year-over-year, and technology access revenue is estimated to grow around 40% year-over-year.

Revenue, margin and EBITDA Improvement versus H1 run rate:

During the second quarter we increased the pricing of certain ingredients and we are also planning price increases for our consumer portfolio with an estimated combined contribution of $10 million in the second half. Additionally, we are implementing cost reduction actions with an estimated impact of $40 million comprising global supply chain and logistics enhancements that include freight and logistics optimization and the consolidation of manufacturing, global purchasing and reduction of packaging costs. We also have identified substantial opportunities to reduce overall marketing spend as a result of the rapidly changing digital media landscape and through portfolio leverage. Total EBITDA impact for the second half of 2022 is estimated to be $50 million and $175 million annualized for 2023.

Conference Call

Amyris will host a conference call today at 9:00 am ET (6:00 am PT) to discuss its Q2 2022 financial results and provide a business and financial update.

Live audio webcast/conference call:

Webcast: please visit http://investors.amyris.com.
U.S. Dial-In Number: (844) 850-0551. International Dial-In Number: (412) 902-4203.

Please connect to the website or dial in to the conference call 15 minutes prior to the start of the call to avoid connection delays. If a participant will be listen-only, they are encouraged to listen via the webcast on Amyris' investor page.

A replay of the webcast will be available on the Investor Relations section of Amyris' website.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

To supplement our financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures that we believe are helpful in understanding our financial results. These non-GAAP financial measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris' historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures, when considered together with financial information prepared in accordance with GAAP, can enhance investors' and analysts' abilities to meaningfully compare our results from period to period, identify operating trends in our business, and track and model our financial performance. In addition, our management believes that these non-GAAP financial measures allow for greater transparency into the indicators used by management to understand and evaluate our business and make operating decisions.

Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris' operating performance. A reconciliation of the non-GAAP financial measures presented in this release to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.

Our Non-GAAP financial measures include the following:

Non-GAAP Gross Margin (Gross Margin) is calculated as GAAP revenue less non-GAAP cost of products sold divided by GAAP revenue. Non-GAAP cost of products sold excludes other costs/provisions, inventory lower of cost or net realizable value adjustments, excess capacity, manufacturing capacity fee adjustments, stock-based compensation expense, depreciation and amortization

Non-GAAP Cash Operating Expense is calculated as GAAP Operating Expense minus non-cash stock-based compensation, depreciation and amortization, non-recurring transaction and acquisition expense, contract credit loss reserve, and R&D performance agreement termination.

EBITDA is calculated as GAAP net income (loss) less interest, expense, income tax expense, depreciation and amortization expense, and loss allocated to participating securities.

Adjusted EBITDA is calculated as EBITDA less income attributable to noncontrolling interest, gain/loss from change in fair value of derivatives, gain/loss from changes in the fair value of debt, loss upon debt extinguishment, other income/expense, loss from investment in affiliate, inventory lower of cost or net realizable value adjustments, non-recurring transaction and acquisition expense, stock-based compensation expense, R&D performance agreement termination, manufacturing capacity fee adjustment and contract asset credit loss reserve.

Adjusted net income (loss) is calculated as GAAP net income/loss excluding stock-based compensation expense, gain/loss from change in fair value of derivatives, gain/ loss from changes in the fair value of debt, losses upon debt extinguishment, income/loss attributable to noncontrolling interest, loss allocated to participating securities, inventory lower of cost or net realizable value adjustments, R&D performance agreement termination, manufacturing capacity fee adjustments, non-recurring transaction and acquisition expense, other income/expense, and gain/loss from investment in affiliate.

Adjusted EPS is calculated by dividing adjusted net income (loss) by the weighted average shares, basic outstanding for the period.

About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-MarketTM technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo, Biossance, JVN, Lab-to-Market, , MenoLabs and Rose Inc. are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris' financial outlook for 2022; Amyris' 2022 goals and future milestones, including actions to reduce costs and improve EBITDA in H2 2022, price increases and reductions in spend; Amyris' expectations regarding potential funding transactions to provide liquidity, the timing thereof and potential proceeds therefrom; and Amyris' expectations regarding efforts to mitigate supply chain issues, reduce freight expense and improve overall resiliency. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to fund operating and capital expenses, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to the COVID-19 pandemic and any other geopolitical events, including Russia's invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results or cause market volatility, risks related to Amyris' reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Financial Tables Follow

 

Amyris, Inc. 



CONDENSED CONSOLIDATED BALANCE SHEETS



(In thousands

June 30, 2022

December 31, 2021

Assets



Current assets:



Cash and cash equivalents

$         99,820

$                483,462

Restricted cash

1,090

199

Accounts receivable, net

41,125

37,074

Accounts receivable - related party, net

5,001

5,667

Contract assets

3,946

4,227

Contract assets - related party

15,265

-

Inventories

99,195

75,070

Prepaid expenses and other current assets

44,667

33,513

Total current assets

310,109

639,212

Property, plant and equipment, net

151,137

72,835

Restricted cash, noncurrent

5,633

4,651

Recoverable taxes from Brazilian government entities

22,038

16,740

Right-of-use assets under financing leases, net

393

7,342

Right-of-use assets under operating leases, net

90,070

32,428

Goodwill

134,164

131,259

Intangible assets, net

57,645

39,265

Other assets

18,251

10,566

Total assets

$       789,440

$                954,298

Liabilities, Mezzanine Equity and Stockholders' (Deficit) Equity



Current liabilities:



Accounts payable

$       102,962

$                  79,666

Accrued and other current liabilities

80,689

71,457

Financing lease liabilities

12

140

Operating lease liabilities

1,640

7,689

Contract liabilities

816

2,530

Debt, current portion

955

896

Related party debt, current portion

-

107,427

Total current liabilities

187,074

269,805

Long-term debt, net of current portion

672,965

309,061

Related party debt, net of current portion

51,516

-

Financing lease liabilities, net of current portion

54

61

Operating lease liabilities, net of current portion

75,285

19,829

Derivative liabilities

1,649

7,062

Acquisition-related contingent consideration

40,275

64,762

Other noncurrent liabilities

4,210

4,510

Total liabilities

1,033,028

675,090

Commitments and contingencies



Mezzanine equity:



Contingently redeemable common stock

5,000

5,000

Redeemable noncontrolling interest

31,004

28,520

Stockholders' (deficit) equity:



Common stock

32

31

Additional paid-in capital

2,357,311

2,656,838

Accumulated other comprehensive loss

(61,351)

(52,769)

Accumulated deficit

(2,568,986)

(2,357,661)

Total Amyris, Inc. stockholders' (deficit) equity

(272,994)

246,439

Noncontrolling interest

(6,598)

(751)

Total stockholders' (deficit) equity

(279,592)

245,688

Total liabilities, mezzanine equity and stockholders' (deficit) equity

$       789,440

$                954,298

 

Amyris, Inc. 






CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)







Three Months Ended June 30,


Six Months Ended June 30,

(In thousands, except shares and per share amounts)

2022

2021


2022

2021

Revenue:






Renewable products

$        54,390

$        37,172


$        97,855

$        65,351

Licenses and royalties

6,454

11,000


15,767

154,800

Collaborations, grants and other

4,363

4,144


9,294

9,024

Total revenue

65,207

52,316


122,916

229,175

Cost and operating expenses:






Cost of products sold(1)

55,930

30,421


104,925

53,080

Research and development(1)

26,111

22,424


52,469

45,756

Sales, general and administrative(1)

126,587

54,340


233,503

92,262

Total cost and operating expenses

208,628

107,185


390,897

191,098

(Loss) income from operations

(143,421)

(54,869)


(267,981)

38,077

Other income (expense):






Interest expense

(5,304)

(4,723)


(10,567)

(10,536)

Gain (loss) from change in fair value of derivative instruments

3,598

5,141


5,413

(17,604)

Gain (loss) from change in fair value of debt

35,114

70,132


55,910

(256,653)

Gain (loss) upon extinguishment of debt

-

935


-

(26,378)

Other income (expense), net

780

28


(2,272)

(650)

Total other income (expense), net

34,188

71,513


48,484

(311,821)

(Loss) income before income taxes and loss from investment in affiliate

(109,233)

16,644


(219,497)

(273,744)

Benefit from (provision for) income taxes

685

(57)


1,505

(112)

Loss from investment in affiliate

(4,972)

(1,140)


(5,761)

(748)

Net (loss) income

(113,520)

15,447


(223,753)

(274,604)

Less: loss (income) attributable to noncontrolling interest

3,507

(66)


6,435

(1,266)

Net (loss) income attributable to Amyris, Inc.

(110,013)

15,381


(217,318)

(275,870)

Less: (income) loss allocated to participating securities

-

(13)


-

1,086

Net (loss) income attributable to Amyris, Inc. common stockholders, basic

$    (110,013)

$        15,368


$    (217,318)

$    (274,784)







Weighted-average shares of common stock outstanding used in computing income (loss) per share of common stock, basic

319,916,244

320,088,143


316,425,739

279,819,520

(Loss) income per share attributable to common stockholders, basic

$          (0.34)

$            0.05


$          (0.69)

$          (0.98)







Weighted-average shares of common stock outstanding used in computing loss per share of common stock, diluted

336,642,879

338,807,849


335,798,276

279,819,520

Loss per share attributable to common stockholders, diluted

$          (0.44)

$          (0.16)


$          (0.80)

$          (0.98)







(1) Includes stock-based compensation expense as follows:






Cost of products sold

$               81

$               73


$             159

$             137

Research and development 

1,784

1,318


3,401

2,380

Sales, general and administrative

10,782

7,355


20,675

10,511


$        12,647

$          8,746


$        24,235

$        13,028







Amyris, Inc. 






RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)







Three Months Ended June 30,


Six Months Ended June 30,

(In thousands, except per share data)

2022

2021


2022

2021

Net (loss) income attributable to Amyris, Inc. common stockholders - Basic (GAAP)

$    (110,013)

$        15,368


$    (217,318)

$    (274,784)

Non-GAAP adjustments:






Loss allocated to participating securities

-

13


-

(1,086)

Non-recurring transaction and acquisition expense

-

3,306


-

3,306

Manufacturing capacity fee adjustment

1,204

-


2,616

1,482

Inventory lower-of-cost-or-net realizable value adjustment

611

(1,072)


(355)

(1,233)

R&D Performance Agreement termination

-

-


-

1,850

Hand sanitizer write-off

-

516


(94)

516

M&A transaction legal expense

224

-


2,059

-

Stock-based compensation expense

12,647

8,746


24,235

13,028

(Gain) loss from change in fair value of derivative instruments

(3,598)

(5,141)


(5,413)

17,604

(Gain) loss from change in fair value of debt

(35,114)

(70,132)


(55,910)

256,653

(Gain) loss upon extinguishment of debt

-

(935)


-

26,378

Income (loss) attributable to noncontrolling interest

(3,507)

66


(6,435)

1,266

Other expense, net, and loss (gain) from investment in affiliate, net

4,192

1,112


8,033

1,398

Net (loss) income attributable to Amyris, Inc. common stockholders (non-GAAP)

$    (133,354)

$      (48,153)


$    (248,582)

$        46,378







Weighted-average shares outstanding






Weighted-average shares of common stock outstanding used in computing loss per share attributable to Amyris, Inc. common stockholders, basic (GAAP and non-GAAP)

319,916,244

320,088,143


316,425,739

279,819,520







(Loss) earnings per share attributable to Amyris, Inc. common stockholders - Basic (GAAP)

$          (0.34)

$            0.05


$          (0.69)

$          (0.98)

Non-GAAP adjustments:






Loss allocated to participating securities

-

0.00


-

(0.00)

Non-recurring transaction and acquisition expense

-

0.01


-

0.01

Manufacturing capacity fee adjustment

0.00

-


0.01

0.01

Inventory lower-of-cost-or-net realizable value adjustment

0.00

(0.00)


(0.00)

(0.00)

R&D Performance Agreement termination

-

-


-

0.01

Hand sanitizer write-off

-

0.00


(0.00)

0.00

M&A transaction legal expense

0.00

-


0.01

-

Stock-based compensation expense

0.04

0.03


0.08

0.05

(Gain) loss from change in fair value of derivative instruments

(0.01)

(0.02)


(0.02)

0.06

(Gain) loss from change in fair value of debt

(0.11)

(0.22)


(0.18)

0.92

(Gain) loss upon extinguishment of debt

-

(0.00)


-

0.09

Income (loss) attributable to noncontrolling interest

(0.01)

0.00


(0.02)

0.00

Other expense, net, and loss (gain) from investment in affiliate, net

0.01

0.00


0.03

0.00

(Loss) earnings per share attributable to Amyris, Inc. common stockholders (non-GAAP)(1)

$          (0.42)

$          (0.15)


$          (0.79)

$            0.17

(1) Amounts may not sum due to rounding.

-

-


-

-


Three Months Ended June 30,


Six Months Ended June 30,

ADJUSTED EBITDA

2022

2021


2022

2021

GAAP net (loss) income attributable to Amyris, Inc. common stockholders - Basic

$    (110,013)

$        15,368


$    (217,318)

$    (274,784)

Interest expense

5,304

4,723


10,567

10,536

Income taxes

(685)

57


(1,505)

112

Depreciation and amortization

3,770

2,322


7,062

4,435

Loss allocated to participating securities

-

13


-

(1,086)

EBITDA

(101,624)

22,483


(201,194)

(260,787)

Manufacturing capacity fee adjustment

1,204

-


2,616

1,482

Inventory lower-of-cost-or-net realizable value adjustment

611

(1,072)


(355)

(1,233)

Hand sanitizer write-off

-

516


(94)

516

R&D Performance Agreement termination

-

-


-

1,850

Non-recurring transaction and acquisition expense

-

3,306


-

3,306

M&A transaction legal expense

224

-


2,059

-

Stock-based compensation expense

12,647

8,746


24,235

13,028

(Gain) loss from change in fair value of derivative instruments and debt, (gain) loss upon extinguishment of debt, other (income) expense, and (gain) loss from investment in affiliate

(34,520)

(75,096)


(53,290)

302,033

(Loss) income attributable to noncontrolling interest

(3,507)

66


(6,435)

1,266

Adjusted EBITDA

$    (124,965)

$      (41,051)


$    (232,458)

$        61,461

 

Amyris, Inc. 






RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)







Three Months Ended June 30,


Six Months Ended June 30,

(In thousands)

2022

2021


2022

2021

Revenue (GAAP and non-GAAP)






Renewable products

$   54,390

$ 37,172


$   97,855

$   65,351

Licenses and royalties

6,454

11,000


15,767

154,800

Collaborations, grants and other

4,363

4,144


9,294

9,024

Revenue (GAAP and non-GAAP)

$   65,207

$ 52,316


$ 122,916

$ 229,175







Cost of products sold (GAAP)

$   55,930

$ 30,421


$ 104,925

$   53,080

Other costs and provisions

(15,938)

(3,692)


(32,461)

(8,165)

Manufacturing capacity fee adjustment

(1,204)

-


(2,616)

(1,482)

Hand sanitizer write-off

-

(516)


94

(516)

Excess capacity

(748)

(832)


(1,411)

(1,037)

Inventory lower-of-cost-or-net realizable value adjustment

(611)

1,072


355

1,233

Stock-based compensation expense

(81)

(73)


(159)

(137)

Depreciation and amortization

(526)

(550)


(1,016)

(1,064)

Cost of products sold (non-GAAP)

$   36,822

$ 25,830


$   67,711

$   41,912







Adjusted gross profit (non-GAAP)

$   28,385

$ 26,486


$   55,205

$ 187,263

Gross margin %

44 %

51 %


45 %

82 %







Research and development expense (GAAP)

$   26,111

$ 22,424


$   52,469

$   45,756

Stock-based compensation expense

(1,784)

(1,318)


(3,401)

(2,380)

Depreciation and amortization

(1,611)

(1,350)


(3,093)

(2,671)

R&D performance agreement termination

-

-


-

(1,850)

Research and development expense (non-GAAP)

$   22,716

$ 19,756


$   45,975

$   38,855







Sales, general and administrative expense (GAAP)

$ 126,587

$ 54,340


$ 233,503

$   92,262

Stock-based compensation expense

(10,782)

(7,355)


(20,675)

(10,511)

Depreciation and amortization

(1,633)

(422)


(2,953)

(700)

Non-recurring transaction and acquisition expense

-

(3,306)


-

(3,306)

M&A transaction legal expense

(224)

-


(2,059)

-

Sales, general and administrative expense (non-GAAP)

$ 113,948

$ 43,257


$ 207,816

$   77,745







Cash operating expense

$ 136,664

$ 63,013


$ 253,791

$ 116,600

 

SOURCE Amyris, Inc.

For further information: Investors: Amyris, Inc., Paul Vincent, vincent@amyris.com, +1 (510) 450-0761, Argot Partners, Jason Finkelstein, amyris@argotpartners.com, +1 (212) 600-1902, Media: Amyris, Inc., Beth Bannerman, bannerman@amyris.com, +1 (510) 914-0022
Contact Us

Beth Bannerman
Chief Engagement & Sustainability Officer
Amyris, Inc. 
pr@amyris.com